Completed
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Led by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Updated on 2015-12-15
27
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study has been important in establishing synthetic human parathyroid hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with calcium and calcitriol. Providing synthetic human parathyroid hormone 1-34 (PTH) to patients who are unresponsive to conventional therapy has enabled severe cases of hypoparathyroidism to be managed effectively with the investigational drug, PTH. The primary goals of this study are to (1) provide long-term PTH therapy to patients who do not respond to conventional therapy; (2) understand the long-term effect of therapeutic PTH replacement on kidney function and bone mineral density; (3) study and track linear growth and bone accrual in children with hypoparathyroidism. (4) determine if subjects reach a normal level of peak bone mass and if the timing of this is comparable to normal age-matched healthy controls.
CONDITIONS
Brief Title
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Who Can Participate
Eligibility Criteria
- INCLUSION CRITERIA:
This study will include patients (ages 17-69) with biochemically confirmed hypoparathyroidism.
EXCLUSION CRITERIA
Women who are pregnant will be excluded.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here